166 related articles for article (PubMed ID: 28855498)
1. TRAF2 is a Valuable Prognostic Biomarker in Patients with Prostate Cancer.
Wei B; Liang J; Hu J; Mi Y; Ruan J; Zhang J; Wang Z; Hu Q; Jiang H; Ding Q
Med Sci Monit; 2017 Aug; 23():4192-4204. PubMed ID: 28855498
[TBL] [Abstract][Full Text] [Related]
2. CPNE1 Is a Useful Prognostic Marker and Is Associated with TNF Receptor-Associated Factor 2 (TRAF2) Expression in Prostate Cancer.
Liang J; Zhang J; Ruan J; Mi Y; Hu Q; Wang Z; Wei B
Med Sci Monit; 2017 Nov; 23():5504-5514. PubMed ID: 29151113
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of TNF receptor-associated factor 2 (TRAF2) modulates in vitro growth of TRAIL-treated prostate cancer cells.
Wei B; Ruan J; Mi Y; Hu J; Zhang J; Wang Z; Hu Q; Jiang H; Ding Q
Biomed Pharmacother; 2017 Sep; 93():462-469. PubMed ID: 28667915
[TBL] [Abstract][Full Text] [Related]
4. High BIRC7 Expression Might Be an Independent Prognostic Indicator of Poor Recurrence-Free Survival in Patients With Prostate Cancer.
Yang Y; Sun P; Xu W; Xia W
Technol Cancer Res Treat; 2018 Jan; 17():1533033818809694. PubMed ID: 30376767
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of TNFR-Associated Factor 1 and 2 (TRAF1 and TRAF2) in Glioblastoma.
Zhang W; Sun Y; Liu L; Li Z
Med Sci Monit; 2017 Sep; 23():4506-4512. PubMed ID: 28926524
[TBL] [Abstract][Full Text] [Related]
6. Methylation status of TRAF2 is associated with the diagnosis and prognosis of gastric cancer.
Zhang J; Dai WJ; Yang XZ
Int J Clin Exp Pathol; 2015; 8(11):14228-34. PubMed ID: 26823737
[TBL] [Abstract][Full Text] [Related]
7. Asporin is a stromally expressed marker associated with prostate cancer progression.
Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
[TBL] [Abstract][Full Text] [Related]
9. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.
Zhang W; Shu P; Wang S; Song J; Liu K; Wang C; Ran L
Gene; 2018 Oct; 675():136-143. PubMed ID: 29966681
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of TRAIL signalling molecules in cervical squamous cell carcinoma.
Yao Q; Du J; Lin J; Luo Y; Wang Y; Liu Y; Zhang B; Ren C; Liu C
J Clin Pathol; 2016 Feb; 69(2):122-7. PubMed ID: 26254281
[TBL] [Abstract][Full Text] [Related]
11. Low-molecular-weight Protein Tyrosine Phosphatase Is a Possible Biomarker for Predicting Postoperative Biochemical Recurrence in Prostate Cancer With Negative Surgical Margins.
Kurose H; Ueda K; Kondo R; Ogasawara S; Kusano H; Sanada S; Naito Y; Akiba J; Kakuma T; Igawa T; Yano H
Anticancer Res; 2019 Feb; 39(2):957-964. PubMed ID: 30711981
[TBL] [Abstract][Full Text] [Related]
12. Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy.
Chen WY; Hua KT; Lee WJ; Lin YW; Liu YN; Chen CL; Wen YC; Chien MH
Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27455254
[TBL] [Abstract][Full Text] [Related]
13. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy.
Yu L; Toriseva M; Tuomala M; Seikkula H; Elo T; Tuomela J; Kallajoki M; Mirtti T; Taimen P; Boström PJ; Alanen K; Nurmi M; Nees M; Härkönen P
Int J Cancer; 2016 Jul; 139(1):140-52. PubMed ID: 26891277
[TBL] [Abstract][Full Text] [Related]
15. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of both tumor and stromal expression of components of the IL-1 and TNF-α signaling pathways in prostate cancer.
Rodríguez-Berriguete G; Sánchez-Espiridión B; Cansino JR; Olmedilla G; Martínez-Onsurbe P; Sánchez-Chapado M; Paniagua R; Fraile B; Royuela M
Cytokine; 2013 Nov; 64(2):555-63. PubMed ID: 24063999
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
[TBL] [Abstract][Full Text] [Related]
19. High Expression of KIF22/Kinesin-Like DNA Binding Protein (Kid) as a Poor Prognostic Factor in Prostate Cancer Patients.
Zhang Z; Xie H; Zhu S; Chen X; Yu J; Shen T; Li X; Shang Z; Niu Y
Med Sci Monit; 2018 Nov; 24():8190-8197. PubMed ID: 30427826
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
